|
US6482404B1
(en)
|
1989-10-12 |
2002-11-19 |
David James White |
Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
|
|
US5866402A
(en)
*
|
1995-05-05 |
1999-02-02 |
Chiron Corporation |
Chimeric MCP and DAF proteins with cell surface localizing domain
|
|
FR2736916B1
(fr)
*
|
1995-07-21 |
1997-09-19 |
Univ Paris Curie |
Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
|
|
DE69828615T2
(de)
*
|
1997-10-31 |
2005-12-01 |
Walter Reed Army Institute Of Research |
Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
|
|
US6956107B2
(en)
*
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
EP3056516A1
(en)
*
|
1998-02-20 |
2016-08-17 |
Genentech, Inc. |
Inhibitors of complement activation
|
|
US7112327B2
(en)
*
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
US6297024B1
(en)
|
1998-10-15 |
2001-10-02 |
Cell Activation, Inc. |
Methods for assessing complement activation
|
|
US6235494B1
(en)
|
1999-02-08 |
2001-05-22 |
The Scripps Research Institute |
Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
|
|
EP1228237A1
(en)
*
|
1999-11-01 |
2002-08-07 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
ATE449791T1
(de)
|
2000-10-10 |
2009-12-15 |
Genentech Inc |
Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
|
|
US6820011B2
(en)
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
|
ES2322442T3
(es)
*
|
2001-06-08 |
2009-06-22 |
Novartis Ag |
Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
|
|
EP1539811A4
(en)
*
|
2002-09-16 |
2006-05-24 |
Elusys Therapeutics Inc |
PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
|
|
CN100594037C
(zh)
|
2002-11-15 |
2010-03-17 |
Musc研究发展基金会 |
通过补体受体2定向的补体调节剂
|
|
WO2005069726A2
(en)
|
2004-01-21 |
2005-08-04 |
Case Western Reserve University |
Hybrid and chimeric polypeptides that regulate activation of complement
|
|
BRPI0506629A
(pt)
*
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
US8703693B2
(en)
*
|
2004-03-31 |
2014-04-22 |
The Feinstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
|
CA2562957C
(en)
*
|
2004-03-31 |
2013-05-21 |
The Feinstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
|
CN103505728A
(zh)
*
|
2005-05-26 |
2014-01-15 |
科罗拉多大学评议会法人机构 |
用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
|
|
DK2500030T4
(en)
*
|
2005-11-04 |
2018-10-29 |
Genentech Inc |
Use of complement pathway inhibitors for the treatment of eye diseases
|
|
JP5250548B2
(ja)
*
|
2006-06-21 |
2013-07-31 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
疾患の治療のための補体ｈ因子の標的化
|
|
CN106084055A
(zh)
|
2006-11-02 |
2016-11-09 |
健泰科生物技术公司 |
人源化的抗‑d因子抗体
|
|
MX2009009200A
(es)
*
|
2007-03-01 |
2009-10-28 |
Advanced Vision Therapies Inc |
Tratamiento de enfermedades caracterizadas por la inflamacion.
|
|
WO2008140653A2
(en)
*
|
2007-03-14 |
2008-11-20 |
Taligen Therapeutics, Inc. |
Humaneered anti-factor b antibody
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
WO2009151634A1
(en)
*
|
2008-06-12 |
2009-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
JP5871798B2
(ja)
|
2009-07-02 |
2016-03-01 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
肝再生を刺激する方法
|
|
CN102958535A
(zh)
|
2009-11-05 |
2013-03-06 |
亚力史剑桥公司 |
阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
|
|
CN102234332B
(zh)
*
|
2010-04-26 |
2014-12-17 |
浙江海正药业股份有限公司 |
一种重组人血白蛋白及其融合蛋白的分离纯化工艺
|
|
MX2012013233A
(es)
|
2010-05-14 |
2013-05-20 |
Univ Colorado Regents |
Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
|
|
BR112012033119A2
(pt)
|
2010-06-22 |
2016-10-25 |
Univ Colorado Regents |
anticorpos para o fragamento c3d do componente do complemento 3.
|
|
CN106620693A
(zh)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
|
CA2840270C
(en)
|
2011-06-22 |
2023-09-26 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US9243070B2
(en)
|
2012-04-03 |
2016-01-26 |
Novelmed Therapeutics, Inc. |
Humanized and chimeric anti-factor Bb antibodies and uses thereof
|
|
US9803005B2
(en)
|
2012-05-24 |
2017-10-31 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
|
JP2015535212A
(ja)
|
2012-08-17 |
2015-12-10 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
補体活性化を検出するための組成物および方法
|
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
|
AU2015223056B2
(en)
|
2014-02-27 |
2020-10-01 |
Allergan, Inc. |
Complement Factor Bb antibodies
|
|
SG11201608868PA
(en)
|
2014-05-01 |
2016-11-29 |
Genentech Inc |
Anti-factor d antibody variants and uses thereof
|
|
BR112017011170A2
(pt)
|
2014-12-18 |
2018-02-27 |
Hoffmann La Roche |
método para determinar a citotoxicidade dependente do complemento de uma composição
|
|
EP3359663A4
(en)
|
2015-09-24 |
2019-08-14 |
The Trustees of The University of Pennsylvania |
COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
|
|
JP2018536650A
(ja)
|
2015-10-30 |
2018-12-13 |
ジェネンテック， インコーポレイテッド |
抗ｄ因子抗体変異体コンジュゲート及びその使用
|
|
TW201730211A
(zh)
|
2015-10-30 |
2017-09-01 |
建南德克公司 |
抗因子d抗體及結合物
|
|
LT3394089T
(lt)
*
|
2015-12-23 |
2021-11-25 |
eleva GmbH |
Polipeptidai, skirti komplemento aktyvacijos inhibicijai
|
|
CA3029106A1
(en)
*
|
2016-06-28 |
2018-01-04 |
Universitat Ulm |
Complement inhibitors and uses thereof
|
|
GB201800620D0
(en)
|
2018-01-15 |
2018-02-28 |
Univ Manchester |
C3b Binding Polypeptide
|
|
JP7444968B2
(ja)
*
|
2019-04-13 |
2024-03-06 |
ナショナル・センター・フォー・セル・サイエンス |
Ｄａｆ－ｍｃｐキメラタンパク質、その製造方法及び補体系が関係する病的状態を処置するためのキメラタンパク質の使用
|